A fresh discovery at Spur has put the Lachlan Fold Belt back in play, with juniors scrambling to prove up the next big hit.

A UBS analysis shows that five leading healthcare stocks outperformed the S&P/ASX200 index during previous market crises.

After more than 15 years of setbacks, Mesoblast has finally secured its first FDA approval, and early signs suggest the commercial rollout is gaining traction.

Rhythm Biosciences (ASX:RHY) vision is starting to take flight as Pitt Street values Rhythm at more than double its current ...

The ASX is taking its chances with Trump’s 5-day pause in Iran, piling back in on the first hint the conflict could be nearing an end.

Trump flips and markets pile back in ; Oil drops 10% but tension still there ; Miners rebound hard while energy gets hit; The S&P/ASX 200 came out of the gates like it had somethi ...

Anson Resources' (ASX:ASN) drilling program at the Yellow Cat project aims to confirm mineralisation extensions.

Biotech catches a break, with Amplia’s trial results lifting sentiment as psychedelics edge further into the mainstream.

From virtual fences which use collars to keep livestock away from boundaries, to a new standard for scoring the quality of ...

The ASX has slipped into correction territory as metals slump, oil surges and fresh geopolitical tensions rattle early trade ...

Mineral potential and a 'tough but fair' stance on new digs has snared South Australia top spot in a global investment report ...

Killi set to gain impetus after hiring mining industry top guns ; Approval granted to Felix for bulk sampling at NW Array in ...